Dutasteride has a terminal elimination half-life of approximately 5 weeks (about 35 days) at steady state. That is more than a hundred times longer than finasteride, whose label gives a mean terminal half-life of approximately 5 to 6 hours in men aged 18 to 60 and about 8 hours in men over 70. On daily dosing, dutasteride serum concentrations reach 65% of steady state after 1 month and approximately 90% after 3 months. After the last dose, serum concentrations remain detectable, above 0.1 ng/mL, for up to 4 to 6 months. Dutasteride is FDA-approved in the United States for bph/">benign prostatic hyperplasia only; use for hair loss is off-label.
Understanding the Half-Life
A drug’s half-life is the time it takes for the concentration in the body to reduce by half. For dutasteride, this is approximately 35 days. This means:
- After 35 days (1 half-life): 50% of a single dose remains
- After 70 days (2 half-lives): ~25% remains
- After 105 days (3 half-lives): ~12.5% remains
- After 175 days (5 half-lives): about 3% remains. The label’s own statement is that serum concentrations stay detectable for up to 4 to 6 months after treatment stops
Because of this long half-life, dutasteride accumulates over months of daily dosing. The label gives the accumulation curve directly: serum concentrations reach 65% of steady state after 1 month and approximately 90% after 3 months. The average steady-state serum concentration was 40 ng/mL after 0.5 mg daily for 1 year. Semen concentrations reached steady state on a similar schedule, at 6 months.
Dutasteride Half-Life vs Finasteride
| Property | Dutasteride | Finasteride |
|---|---|---|
| Terminal half-life | ~5 weeks (about 35 days) at steady state | ~5-6 hours (men 18-60), ~8 hours (men over 70) |
| Accumulation on daily dosing | 65% of steady state at 1 month, ~90% at 3 months | Label describes a slow accumulation phase; no figure given |
| Detectable in serum after last dose | Up to 4 to 6 months (above 0.1 ng/mL) | Not stated in the label |
| Volume of distribution | 300 to 500 L | 76 L (mean, steady state) |
| Plasma protein binding | 99.0% to albumin, 96.6% to alpha-1 acid glycoprotein | Approximately 90% |
Practical Implications of the Long Half-Life
Missing a dose
A terminal half-life of roughly 35 days means one missed 0.5 mg dose is a small fraction of the accumulated body burden. The label does not give missed-dose instructions, and it does not describe any dosing schedule other than 0.5 mg once daily. Do not double up to compensate without asking your prescriber. More on missed doses.
PSA testing
Dutasteride reduces serum PSA (prostate-specific antigen) by approximately 50% within 3 to 6 months of treatment. The label directs that a new PSA baseline be established at least 3 months after starting, with periodic monitoring thereafter, and that an isolated PSA value in a man treated for 3 months or more be doubled for comparison with normal ranges in untreated men. Because serum concentrations stay detectable for up to 4 to 6 months after the last dose, a PSA drawn shortly after stopping should be interpreted with that in mind.
Stopping treatment
The label describes no taper and no withdrawal schedule for dutasteride. What it does establish is that serum concentrations remain detectable for up to 4 to 6 months after the last dose, so any effect that depends on DHT suppression, including the off-label hair-loss effect, does not switch off on the day you stop. The label gives no timeline for the return of DHT or for any change in hair, and none is asserted here. Full discontinuation guide.
Fertility and blood donation
The long half-life has important implications for fertility planning and blood donation:
- Fertility: The label records mean reductions at 52 weeks of 23% in total sperm count, 26% in semen volume and 18% in sperm motility, with sperm concentration and morphology unaffected, and states that the clinical significance for an individual patient’s fertility is not known. It sets no timing rule for conception. Dutasteride and fertility guide.
- Blood donation: The label states men treated with dutasteride should not donate blood until at least 6 months have passed since their last dose, to prevent administration of dutasteride to a pregnant female transfusion recipient. The American Red Cross lists the same 6-month wait. Blood donation guidelines.
- PSA before a procedure: Tell any clinician interpreting your PSA that you have taken dutasteride within the past 6 months. The label’s doubling rule and the persistence of detectable serum concentrations both bear on how that result should be read.
Side effect offset
No recovery timeline for side effects after stopping appears in the dutasteride label, and none is invented here. What the pharmacokinetics establish is the floor: serum concentrations remain detectable for up to 4 to 6 months after the last dose, against hours for finasteride. The label also notes that its sexual adverse reactions may persist after discontinuation and that the role of dutasteride in that persistence is unknown. Are side effects permanent?
Why Is Dutasteride’s Half-Life So Long?
Three properties in the label account for it. Dutasteride is insoluble in water and has a large volume of distribution, 300 to 500 L, so it distributes widely out of plasma. It is highly bound to plasma proteins, 99.0% to albumin and 96.6% to alpha-1 acid glycoprotein. And it is extensively metabolized in the liver by CYP3A4 and CYP3A5 to hydroxylated metabolites (4′-hydroxydutasteride, 6-hydroxydutasteride, 6,4′-dihydroxydutasteride and 15-hydroxydutasteride) plus 1,2-dihydrodutasteride, with excretion mainly in the faeces and only trace amounts of unchanged drug in urine.
Sources
- FDA. Avodart (dutasteride) prescribing information, sections 11, 12.2 and 12.3. accessdata.fda.gov
- FDA. Propecia (finasteride) prescribing information, Clinical Pharmacology. accessdata.fda.gov
- Bramson HN, Hermann D, Batchelor KW, et al. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther. 1997;282(3):1496-502. PubMed
- Clark RV, Hermann DJ, Cunningham GR, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89(5):2179-84. PubMed